AFFILIATIONS
1 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
2 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
3 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
4 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
5 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
6 AstraZeneca Pharmaceuticals, Waltham, Massachusetts, United States, Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
7 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
8 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
9 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
10 Academy of Scientific and Innovative Research, Ghaziabad, Uttar Pradesh, India, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India
11 Academy of Scientific and Innovative Research, Ghaziabad, Uttar Pradesh, India, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India
12 Academy of Scientific and Innovative Research, Ghaziabad, Uttar Pradesh, India, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India
13 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
14 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
15 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
16 The Ohio State University, Columbus, Ohio, United States
17 The Ohio State University, Columbus, Ohio, United States
18 The Ohio State University, Columbus, Ohio, United States
19 Comprehensive Cancer Center, Columbus, Ohio, United States
20 Academy of Scientific and Innovative Research, Ghaziabad, Uttar Pradesh, India, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India
21 The Ohio State University, Columbus, Ohio, United States
22 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
23 Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University, Columbus, Ohio, United States
ABSTRACT
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with dismal prognosis for high/intermediate risk patients.1 Frontline chemotherapy is poorly tolerated by elderly patients, and resistance to targeted therapies like Bruton tyrosine kinase inhibitors (BTKi) and BCL-2 inhibitors (BCL-2i) remains challenging despite improved toxicity.1 Identifying more targetable MCL vulnerabilities becomes crucial. Protein phosphatase 2A (PP2A) is a metabolic regulator suppressed in many cancers through overexpression of endogenous inhibitors.2-4 Our findings suggest that the PP2A inhibitor, SET, is transcriptionally overexpressed in primary MCL (n=66) versus normal cells (n=14, p<0.05). Additionally, patients with high SET expression (n=31) had decreased overall survival (p<0.01), suggesting that PP2A suppression through SET overexpression is an MCL vulnerability. To harness this vulnerability, we designed and produced XML-3D, a first-in-class small molecule that activates PP2A by inhibiting SET/PP2Ac interactions. Co-immunoprecipitation and proximity ligation assays confirmed XML-3D-mediated decrease in PP2Ac/SET interactions, leading to PP2A activation as confirmed by PP2A activity assay. Moreover, XML-3D induced apoptosis in six independent MCL cell lines and primary MCL samples. Parallel MTS viability assays showed impaired mitochondrial activity, which was rescued by okadaic acid (p<0.01, n=3), suggesting PP2A-activation dependence. RNA sequencing in MCL cell lines revealed decreased c-MYC and oxidative phosphorylation (OxPhos) targets (p<0.0001, p<0.05, n=3), particularly electron transport chain complex I subunits. XML-3D decreased total c-MYC and phospho-c-MYC (Ser62), consistent with PP2A-mediated c-MYC dephosphorylation and destabilization,3 and reduced OxPhos as confirmed by Western blotting and metabolism analysis using a Seahorse Extracellular Analyzer. Moreover, the protein expression of top complex I subunits from the sequencing results was dependent on c-MYC as confirmed by siRNA knockdown. These findings suggest that PP2A activation by XML-3D induces cytotoxicity through impairment of OxPhos by destabilizing the MYC/ETC complex I pathway in MCL. Interestingly, Zhang et al have demonstrated that MCL resistance to Bruton’s tyrosine kinase inhibitors (BTKi) is correlated with upregulation of c-MYC and OxPhos targets.5 Increased OxPhos has also been associated with resistance to the BCL-2i Venetoclax in other B cell malignancies such as Chronic Lymphocytic Leukemia (CLL).6 Thus, we generated MCL cell lines resistant to Zanubrutinib (BTKi) and Venetoclax (BCL-2i), currently used against relapsed/refractory MCL and validated OxPhos upregulation. XML-3D suppressed OxPhos and induced apoptosis in all drug-resistant cells in-vitro. Preliminary in-vivo studies suggest that XML-3D slows tumor progression in naive (p<0.01), Zanubrutinib resistant (p<0.01) and Venetoclax resistant (p<0.05) MCL cell-line-derived xenograft (CDX) mouse models. Ongoing studies will further evaluate in-vivo efficacy. Overall, we propose a novel PP2A activation therapeutic strategy that targets metabolic dependencies in treatment-naïve, BTKi-resistant, and BCL-2i-resistant MCL for potential future clinical application.
References
Silkenstedt, E. & Dreyling, M. Treatment of relapsed/refractory MCL. Blood 145, 673–682 (2025).
Cristóbal, I. et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 97, 543–550 (2012).
Goswami, S. et al. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia. Blood 139, 1340–1358 (2022).
Liu, Q. et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111, 275–284 (2008).
Zhang, L. et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci. Transl. Med. 11, eaau1167 (2019).
Chen, Z. et al. Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia. Haematologica 109, 151-162 (2024).